Dr. Roland GeisbergerDr. Roland Geisberger

Supervisor

 

Since Sep 2008

LIMCR, University Hospital Salzburg, Austria. Group leader Tumor Immunology and Chemoimmunotherapy

 

Sep 2006 - Aug 2008

Erwin-Schrödinger fellowship of the FWF for the project J2508 ‘the role of AID in the specific immune respone’ at the MRC/LMB Cambridge/UK in the group of Prof. M Neuberger

 

Sep 2005 - Aug 2006
Post doc position at the GSF, Munich. Research on Thioredoxin Reductase 2-deficient lymphocytes and on the role of Selenium during lymphomagenesis in the group of Dr. J Schmidt/Dr. M Brielmeier

 

Jun 2004 - Jun 2005
Post doc position at the University of Salzburg. Research on the internalisation of the B-cell antigen receptor on mature B cells ( in the group of Dr. G Achatz)

 

Jun 2003 - May 2004
Research on the signaling of neurotransmitters and on the PCR supported diagnosis of infectious diseases in the laboratory of Dr. B Kofler, University Hospital Salzburg

 

Oct 2003
Dr. rer. nat. (Ph.D.) awarded in molecular immunology and genetics

 

Oct 2000 - Oct 2003
Ph.D. thesis at the University of Salzburg ‘Investigation of the membrane Immunoglobulin E as a signal transducing component’ (group of G Achatz)

 

Oct 2000

Mag. rer. nat. (Master’s degree) awarded in genetics

 

Sep 1999 - Okt 2000
diploma thesis at the University of Salzburg ‘Characterization of proteins involved in IgE antigen receptor mediated signalling’

 

Mar 1994

Subscribing Biology at the University of Vienna

 

Grants

 

Jun 2012 - Dec 2015

FWF Project:"regulation of AID by lysine modifications" (P24619)

 

May 2010 - May 2011

PMU-FFF grant with Prof. Dr. Richard Greil: "establishing a mouse model to elucidate AID mediated tumor immune evasion" (Nummer E-09/09/047-GRE)

 

Sep 2006 - Sep 2008

Erwin-Schrödinger-fellowship of the FWF: "role of AID in the specific immune response" (J2508)


Stipendien

Sep 2006 - Sep 2008
Erwin-Schrödinger-fellowship of the FWF: "role of AID in the specific immune response" (J2508)

  • 2017

    The Human NADPH Oxidase, Nox4, Regulates Cytoskeletal Organization in Two Cancer Cell Lines, HepG2 and SH-SY5Y.

    Auer, S, Rinnerthaler, M, Bischof, J, Streubel, MK, Breitenbach-Koller, H, Geisberger, R, Aigner, E, Cadamuro, J, Richter, K, Sopjani, M, Haschke-Becher, E, Felder, TK, Breitenbach, M.
    Front Oncol. 2017, 7:111.

    View this publication in the PUBMED database
  • 2017

    T cell exhaustion: from pathophysiological basics to tumor immunotherapy.

    Catakovic, K, Klieser, E, Neureiter, D, Geisberger, R.
    Cell Commun Signal. 2017, 15(1).

    View this publication in the PUBMED database
  • 2016

    Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis -Masters of Survival and Clonality?.

    Zaborsky, N, Gassner, FJ, Asslaber, D, Reinthaler, P, Denk, U, Flenady, S, Hofbauer, JP, Danner, B, Rebhandl, S, Harrer, A, Geisberger, R, Greil, R, Egle, A.
    Oncotarget. 2016.

    View this publication in the PUBMED database
  • 2016

    CD1d expression on chronic lymphocytic leukemia B cells affects disease progression and induces T cell skewing in CD8 positive and CD4CD8 double negative T cells.

    Zaborsky, N, Gassner, FJ, Asslaber, D, Reinthaler, P, Denk, U, Flenady, S, Hofbauer, JP, Danner, B, Rebhandl, S, Harrer, A, Geisberger, R, Greil, R, Egle, A.
    Oncotarget. 2016.

    View this publication in the PUBMED database
  • 2015

    AID/APOBEC deaminases and cancer.

    Rebhandl, S, Huemer, M, Greil, R, Geisberger, R.
    Oncoscience. 2015, 2(4): 320-333.

    View this publication in the PUBMED database
  • 2015

    CD4+ T cells, but not non-classical monocytes, are dispensable for the development of chronic lymphocytic leukemia in the TCL1-tg murine model.

    Kocher, T, Asslaber, D, Zaborsky, N, Flenady, S, Denk, U, Reinthaler, P, Ablinger, M, Geisberger, R, Bauer, JW, Seiffert, M, Hartmann, TN, Greil, R, Egle, A, Hofbauer, JP.
    Leukemia. 2015, xx.

    View this publication in the PUBMED database
  • 2015

    AIDing cancer treatment: Reducing AID activity via HSP90 inhibition.

    Rebhandl, S, Geisberger, R.
    Eur J Immunol. 2015, 45(8): 2208-2211.

    View this publication in the PUBMED database
  • 2015

    Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model.

    Gassner FJ, Zaborsky N, Catakovic K, Rebhandl S, Huemer M, Egle A, Hartmann TN, Greil R, Geisberger R.
    Br J Haematol. 2015 Aug,170(4):515-22. doi: 10.1111/bjh.13467. Epub 2015 May 4.

    View this publication in the PUBMED database
  • 2015

    AID/APOBEC deaminases and cancer.

    Rebhandl S, Huemer M, Greil R, Geisberger R.
    Oncoscience. 2015 Apr 28,2(4):320-33. eCollection 2015. Review.

    View this publication in the PUBMED database
  • 2014

    Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia.

    Gassner FJ, Zaborsky N, Neureiter D, Huemer M, Melchardt T, Egle A, Rebhandl S, Catakovic K, Hartmann TN, Greil R, Geisberger R.
    Haematologica. 2014 May,99(5):67-9. doi: 10.3324/haematol.2013.098459. Epub 2014 Feb 21.

    View this publication in the PUBMED database
  • 2014

    AID induces intraclonal diversity and genomic damage in CD86(+) chronic lymphocytic leukemia cells.

    Huemer M, Rebhandl S, Zaborsky N, Gassner FJ, Hainzl S, Weiss L, Hebenstreit D, Greil R, Geisberger R.
    Eur J Immunol. 2014 Dec,44(12):3747-57. doi: 10.1002/eji.201344421. Epub 2014 Oct 18.

    View this publication in the PUBMED database
  • 2014

    APOBEC3 signature mutations in chronic lymphocytic leukemia.

    Rebhandl S, Huemer M, Gassner FJ, Zaborsky N, Hebenstreit D, Catakovic K, Grössinger EM, Greil R, Geisberger R.
    Leukemia. 2014 Sep,28(9):1929-32. doi: 10.1038/leu.2014.160. Epub 2014 May 20.

    View this publication in the PUBMED database
  • 2014

    Alternative splice variants of AID are not stoichiometrically present at the protein level in chronic lymphocytic leukemia.

    Rebhandl S, Huemer M, Zaborsky N, Gassner FJ, Catakovic K, Felder TK, Greil R, Geisberger R.
    Eur J Immunol. 2014 Jul,44(7):2175-87. doi: 10.1002/eji.201343853. Epub 2014 Apr 15.

    View this publication in the PUBMED database
  • 2013

    Lenalidomide/Rituximab Maintenance After Induction With Fludarabine/Rituximab In Combination With Escalating Doses Of Lenalidomide In Previously Untreated Chronic Lymphocytic Leukemia (CLL): The Revlirit CLL5 AGMT Phase I/II Study, Final Results

    Vornamen sind ausgeschrieben-ändern? Alexander Egle, Michael Steurer, Franz Josef Gassner, Roland Geisberger, Thomas Melchardt, Lisa Pleyer, Lukas Weiss, Michael A. Fridrik, Josef Thaler, Alois Lang, Richard Greil,
    Blood (ASH Annual Meeting Abstracts). 2013. #4164:

    View this publication in the PUBMED database
  • 2013

    A modified Phenol-chloroform extraction method for isolating circulating cell free DNA of tumor patients.

    Hufnagl C, Stöcher M, Moik M, Geisberger R, Greil R.
    Journal of Nucleic Acids Investigation. 2013. DOI: 10.4081/jnai.2013.e1

    View this publication in the PUBMED database
  • 2012

    Lysine residue at position 22 of the AID protein regulates its class switch activity.

    Geisberger R, Huemer M, Gassner FJ, Zaborsky N, Egle A, Greil R.
    PLoS One. 2012,7(2):e30667. doi: 10.1371/journal.pone.0030667. Epub 2012 Feb 20.

    View this publication in the PUBMED database
  • 2011

    Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia.

    Gassner FJ, Weiss L, Geisberger R, Hofbauer JP, Egle A, Hartmann TN, Greil R, Tinhofer I.
    Cancer Immunol Immunother. 2011 Jan,60(1):75-85. doi: 10.1007/s00262-010-0920-3. Epub 2010 Sep 21.

    View this publication in the PUBMED database
  • 2011

    A Combination of Fludarabine/Rituximab with Escalating Doses of Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia (CLL): The REVLIRIT CLL5 AGMT Phase I/II Study, Clinical and Exploratory Analyses of Induction Results

    Egle, A, Steurer, M, Gassner, F, Geisberger, R, Melchardt, T, Weiss, L, Fridrik, MA, Thaler, J, Lang, A, Greil, R
    BLOOD. 2011, 118(21): 135-136.

    View this publication in the PUBMED database

Tel. +43-(0)57255-25847

Email: r.geisberger@salk.at

 

Responsibility:

LIMCR, Gruppe: Tumorimmunologie und Chemoimmuntherapie